SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Mutation V205C

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

There are 3 clinical trials

Clinical Trials


1 A Study of M-M-R(TM) II at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age

The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine.

NCT00092391 Measles Mumps Rubella Varicella Biological: Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live Biological: Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
MeSH:Rubella Mumps

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) The purpose of this study is to determine the mumps virus strength at the end of shelf-life (expiration date) of an approved vaccine. --- V205C ---

Primary Outcomes

Measure: Neutralizing antibodies to mumps at 6 weeks postvaccination

Time: 6 weeks postvaccination

Secondary Outcomes

Measure: Geometric mean titers to mumps by ELISA at 6 weeks and at 1 year postvaccination

Time: 6 weeks and 1 year postvaccination

2 A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein.

NCT00092404 Measles Mumps Rubella Varicella Biological: measles, mumps, and rubella virus vaccine live Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
MeSH:Rubella

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C ---

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured With Recombinant Human Albumin (rHA) Versus V205C Manufactured With Pooled-Donor Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C --- --- V205C ---

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) The purpose of this trial is to study the safety and immune response to measles, mumps, and rubella in children who were vaccinated with an investigational measles-mumps-rubella live vaccine made with artificially made human protein. --- V205C ---

Primary Outcomes

Measure: Antibody response rates to measles, mumps, and rubella at 6 weeks postvaccination

Time: 6 weeks postvaccination

Secondary Outcomes

Measure: Geometric mean titers to measles, mumps, and rubella by ELISA at 6 weeks postvaccination

Time: 6 weeks postvaccination

3 A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

NCT00109278 Measles Biological: V205C, measles, mumps, and rubella virus vaccine live Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live
MeSH:Measles

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C ---

A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age. --- V205C --- --- V205C ---

A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED) The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin). --- V205C ---

Primary Outcomes

Measure: Antibody response rate to measles at 6 weeks postvaccination

Secondary Outcomes

Measure: Geometric mean titers to measles by ELISA at 6 weeks postvaccination


HPO Nodes